Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature
Konstantin Schlick, Dominik Kiem, Richard Greil
Abstract
Pancreatic adenocarcinoma carries a devastating prognosis. For locally advanced and metastatic disease, several chemotherapeutic regimens are currently being used. Over the past years, novel approaches have included targeting EGFR, NTRK, PARP, K-Ras as well as stroma and fibrosis, leading to approval of NTRK and PARP inhibitors. Moreover, immune check point inhibitors and different combinational approaches involving immunotherapeutic agents are being investigated in many clinical trials. MiRNAs represent a novel tool and are thought to greatly improve management by allowing for earlier diagnosis and for more precise guidance of treatment.
Topics & Concepts
MedicinePancreatic cancerClinical trialDiseaseOncologyImmunotherapyCancerStromaTargeted therapyPARP inhibitorInternal medicineCancer researchBioinformaticsPoly ADP ribose polymeraseBiologyImmunohistochemistryPolymeraseBiochemistryGenePancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers